

- 20 (1) Acetyl-alpha-methylfentanyl;
- 21 (2) Acetylmethadol;
- 22 (3) Allylprodine;
- 23 (4) Alphacetylmethadol, except levo-alphacetylmethadol
24 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);
- 25 (5) Alphameprodine;
- 26 (6) Alphamethadol;
- 27 (7) Alpha-methylfentanyl;
- 28 (8) Alpha-methylthiofentanyl;
- 29 (9) Benzethidine;
- 30 (10) Betacetylmethadol;
- 31 (11) Beta-hydroxyfentanyl;
- 32 (12) Beta-hydroxy-3-methylfentanyl;
- 33 (13) Betameprodine;
- 34 (14) Betamethadol;
- 35 (15) Betaprodine;
- 36 (16) Clonitazene;
- 37 (17) Dextromoramide;
- 38 (18) Diampromide;
- 39 (19) Diethylthiambutene;
- 40 (20) Difenoxyin;
- 41 (21) Dimenoxadol;
- 42 (22) Dimepheptanol;
- 43 (23) Dimethylthiambutene;
- 44 (24) Dioxaphetyl butyrate;



- 45 (25) Dipipanone;
- 46 (26) Ethylmethylthiambutene;
- 47 (27) Etonitazene;
- 48 (28) Etoxeridine;
- 49 (29) Furethidine;
- 50 (30) Hydroxypethidine;
- 51 (31) Ketobemidone;
- 52 (32) Levomoramide;
- 53 (33) Levophenacylmorphan;
- 54 (34) 3-methylfentanyl;
- 55 (35) 3-methylthiofentanyl;
- 56 (36) Morpheridine;
- 57 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 58 (38) Noracymethadol;
- 59 (39) Norlevorphanol;
- 60 (40) Normethadone;
- 61 (41) Norpipanone;
- 62 (42) Para-fluorofentanyl;
- 63 (43) PEPAP
- 64 (1-(-2- * * *phenethyl)-4-phenyl-4-acetoxypiperidine);
- 65 (44) Phenadoxone;
- 66 (45) Phenampromide;
- 67 (46) Phenomorphan;
- 68 (47) Phenoperidine;
- 69 (48) Piritramide;



- 70 (49) Proheptazine;
- 71 (50) Properidine;
- 72 (51) Propiram;
- 73 (52) Racemoramide;
- 74 (53) Thiofentanyl;
- 75 (54) Tilidine;
- 76 (55) Trimeperidine.

77 (b) **Opiate derivatives.** Any of the following opium
78 derivatives, their salts, isomers and salts of isomers, unless
79 specifically excepted, whenever the existence of these salts,
80 isomers and salts of isomers is possible within the specific
81 chemical designation:

- 82 (1) Acetorphine;
- 83 (2) Acetyldihydrocodeine;
- 84 (3) Benzylmorphine;
- 85 (4) Codeine methylbromide;
- 86 (5) Codeine-N-Oxide;
- 87 (6) Cyprenorphine;
- 88 (7) Desomorphine;
- 89 (8) Dihydromorphine;
- 90 (9) Drotebanol;
- 91 (10) Etorphine; (except hydrochloride salt);
- 92 (11) Heroin;
- 93 (12) Hydromorphanol;
- 94 (13) Methyldesorphine;



- 95 (14) Methyldihydromorphine;
96 (15) Monoacetylmorphine;
97 (16) Morphine methylbromide;
98 (17) Morphine methylsulfonate;
99 (18) Morphine-N-Oxide;
100 (19) Myrophine;
101 (20) Nicocodeine;
102 (21) Nicomorphine;
103 (22) Normorphine;
104 (23) Pholcodine;
105 (24) Thebacon.

106 (c) **Hallucinogenic substances.** Any material, compound,
107 mixture or preparation which contains any quantity of the
108 following substances, their salts, isomers (whether optical,
109 positional, or geometric) and salts of isomers, unless
110 specifically excepted, whenever the existence of these salts,
111 isomers and salts of isomers is possible within the specific
112 chemical designation:

- 113 (* * *1) Alpha-ethyltryptamine;
114 (* * *2) 4-bromo-2,5-dimethoxyamphetamine;
115 (* * *3) 4-bromo-2,5- * * *dimethoxyphenethylamine;
116 (* * *4) 2,5-dimethoxyamphetamine;
117 (* * *5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
118 (* * *6) 2,5-dimethoxy-4(n)-propylthiophenethylamine
119 (2C-T-7);



120 (* * *7) 4-methoxyamphetamine;

121 (* * *8) 5-methoxy-3,4-methylenedioxyamphetamine;

122 (* * *9) 4-methyl-2,5-dimethoxyamphetamine;

123 (* * *10) 3,4-methylenedioxyamphetamine;

124 (* * *11) 3,4-methylenedioxymethamphetamine (MDMA);

125 (* * *12) 3,4-methylenedioxy-N-ethylamphetamine (also

126 known as

127 N-ethyl-alpha-methyl-3,4(methylenedioxy) * * *phenethylamine,

128 N-ethyl MDA, MDE, MDEA);

129 (* * *13) N-hydroxy-3,4-methylenedioxyamphetamine

130 (also known as N-hydroxy MDA, N-OHMDA, and

131 N-hydroxy-alpha-methyl-3,4(methylenedioxy) * * *phenethylamine);

132 (* * *14) 3,4,5-trimethoxyamphetamine;

133 (* * *15) 5-methoxy-N,N-dimethyltryptamine

134 (5-MeO-DMT);

135 (* * *16) Alpha-methyltryptamine (Also known as AMT);

136 (* * *17) Bufotenine;

137 (* * *18) Diethyltryptamine;

138 (* * *19) Dimethyltryptamine;

139 (* * *20) 5-methoxy-N,N-diisopropyltryptamine

140 (5-MeO-DIPT);

141 (* * *21) Ibogaine;

142 (* * *22) Lysergic acid diethylamide (LSD);

143 (* * *23) (A) Marihuana;

144 (B) Hashish;



145 (* * *24) Mescaline;
146 (* * *25) Parahexyl;
147 (* * *26) Peyote;
148 (* * *27) N-ethyl-3-piperidyl benzilate;
149 (* * *28) N-methyl-3-piperidyl benzilate;
150 (* * *29) Psilocybin;
151 (* * *30) Psilocyn;
152 (* * *31) Tetrahydrocannabinols, meaning
153 tetrahydrocannabinols contained in a plant of the genus Cannabis
154 (cannabis plant), as well as the synthetic equivalents of the
155 substances contained in the cannabis plant, or in the resinous
156 extractives of such plant, and/or synthetic substances,
157 derivatives, and their isomers with similar chemical structure and
158 pharmacological activity to those substances contained in the
159 plant such as the following:

- 160 (A) 1 cis or trans tetrahydrocannabinol;
161 (B) 6 cis or trans tetrahydrocannabinol;
162 (C) 3,4 cis or trans tetrahydrocannabinol.

163 (Since nomenclature of these substances is not
164 internationally standardized, compounds of these structures,
165 regardless of atomic positions are covered.)

166 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)

167 Until July 1, 2017, processed cannabis plant extract, oil or
168 resin that contains more than fifteen percent (15%) cannabidiol,
169 or a dilution of the resin that contains at least fifty (50)



170 milligrams of cannabidiol per milliliter, and in either case not
171 more than one-half of one percent (0.5%) of tetrahydrocannabinol,
172 may be obtained on the order of a physician and administered to a
173 patient by or under the direction or supervision of the physician
174 if the extract, oil or resin is obtained from plants grown by the
175 National Center for Natural Products Research at the University of
176 Mississippi and dispensed by the Department of Pharmacy Services
177 at the University of Mississippi Medical Center. The physician
178 must be licensed to practice in Mississippi. The National Center
179 for Natural Products Research at the University of Mississippi,
180 the Department of Pharmacy Services at the University of
181 Mississippi Medical Center and the Mississippi Agricultural and
182 Forestry Experiment Station of Mississippi State University are
183 the only entities authorized to possess cannabidiol for research.
184 The provisions of Section 41-29-125 relative to lawful possession
185 of controlled substances, of Section 41-29-137 relative to
186 recordkeeping requirements regarding the dispensing, use or
187 administration of controlled substances, and of Section 41-29-133
188 relative to inventory requirements, all apply.

189 However, the following products are exempted from control:

- 190 (i) THC-containing industrial products
191 (e.g., * * * paper, rope and clothing made from cannabis stalks);
192 (ii) Processed cannabis plant materials used
193 for industrial purposes, such as fiber retted from cannabis stalks
194 for use in manufacturing textiles or rope;



195 (iii) Animal feed mixtures that contain
196 sterilized cannabis seeds and other ingredients (not derived from
197 the cannabis plant) in a formula designed, marketed and
198 distributed for nonhuman consumption; and

199 (iv) Personal care products that contain oil
200 from sterilized cannabis seeds, such as shampoos, soaps, and body
201 lotions (provided that such products do not cause THC to enter the
202 human body);

203 (32) Phencyclidine;

204 (* * *33) Ethylamine analog of phencyclidine (PCE);

205 (* * *34) Pyrrolidine analog of phencyclidine (PHP,
206 PCPy);

207 (* * *35) Thiophene analog of phencyclidine;

208 (* * *36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
209 (TCPy);

210 (37) 4-methylmethcathinone (mephedrone);

211 (38) 3,4-methylenedioxypropylvalerone (MDPV);

212 (* * *39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine
213 (2C-E);

214 (* * *40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine
215 (2C-D);

216 (* * *41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine
217 (2C-C);

218 (* * *42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine
219 (2C-I); or 2,5-dimethoxy-4-iodophenethylamine;



220 (* * *43)
221 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
222 (* * *44)
223 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
224 (* * *45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);
225 (* * *46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine
226 (2C-N);
227 (* * *47)
228 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
229 (48) 3,4-methylenedioxy-N-methylcathinone (methydone);
230 (* * *49)
231 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
232 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
233 (* * *50)
234 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
235 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
236 (* * *51)
237 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or
238 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
239 Cimbi-5);
240 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,
241 4-benzodiazepin-2-one (also known as Phenazepam);
242 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,
243 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene
244 (also known as Etizolam);



245 (* * *54) Salvia divinorum;
246 (* * *55) Synthetic cannabinoids. Unless specifically
247 excepted or unless listed in another schedule, any material,
248 compound, mixture, or preparation which contains any quantity of a
249 synthetic cannabinoid found in any of the following chemical
250 groups, whether or not substituted to any extent, or any of those
251 groups which contain any synthetic cannabinoid salts, isomers, or
252 salts of isomers, whenever the existence of such salts, isomers,
253 or salts of isomers is possible within the specific chemical
254 designation, including all synthetic cannabinoid chemical
255 analogues in such groups:

256 (A) (6aR,10aR)-9-(hydroxymethyl)-6,
257 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
258 chromen-1-ol (also known as HU-210 or
259 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

260 (B) Naphthoylindoles and naphthylmethylinindoles,
261 being any compound structurally derived from 3-(1-naphthoyl)indole
262 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted
263 in the indole ring to any extent, or in the naphthyl ring to any
264 extent;

265 (C) Naphthoylpyrroles, being any compound
266 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not
267 substituted in the pyrrole ring to any extent, or in the naphthyl
268 ring to any extent;



269 (D) Naphthylmethylindenes, being any compound
270 structurally derived from 1-(1-naphthylmethyl)indene, whether or
271 not substituted in the indene ring to any extent or in the
272 naphthyl ring to any extent;

273 (E) Phenylacetylindoles, being any compound
274 structurally derived from 3-phenylacetylindole, whether or not
275 substituted in the indole ring to any extent or in the phenyl ring
276 to any extent;

277 (F) Cyclohexylphenols, being any compound
278 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether
279 or not substituted in the cyclohexyl ring to any extent or in the
280 phenolic ring to any extent;

281 (G) Benzoylindoles, whether or not substituted in
282 the indole ring to any extent or in the phenyl ring to any extent;

283 (H) Adamantoylindoles, whether or not substituted
284 in the indole ring to any extent or in the adamantoyl ring system
285 to any extent;

286 (I) Tetrahydro derivatives of cannabinol and
287 3-alkyl homologues of cannabiniol or of its tetrahydro
288 derivatives, except where contained in cannabis or cannabis
289 resin * * *;

290 (J) 3-Cyclopropylmethanone indole or
291 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by
292 substitution at the nitrogen atom of the indole ring, whether or
293 not further substituted in the indole ring to any extent, whether



294 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl
295 rings to any extent;

296 (K) Quinolinyll ester indoles, being any compound
297 structurally derived from 1H-indole-3carboxylic acid-8-quinolinyll
298 ester, whether or not substituted in the indole ring to any extent
299 or the quinolone ring to any extent;

300 (L) 3-carbozamide-1H-indazoles, whether or not
301 substituted in the indazole ring to any extent and substituted to
302 any degree on the carboxamide nitrogen and
303 3-carboxamide-1H-indoles, whether or not substituted in the indole
304 ring to any extent and substituted to any degree on the
305 carboxamide nitrogen;

306 (M) Cycloalkanemethanone Indoles, whether or not
307 substituted at the nitrogen atom on the indole ring, whether or
308 not further substituted in the indole ring to any extent, whether
309 or not substituted on the cycloalkane ring to any extent.

310 (d) **Depressants.** Unless specifically excepted or unless
311 listed in another schedule, any material, compound, mixture, or
312 preparation which contains any quantity of the following
313 substances having a depressant effect on the central nervous
314 system, including their salts, isomers, and salts of isomers,
315 whenever the existence of such salts, isomers, and salts of
316 isomers is possible within the specific chemical designation:



317 (1) Gamma-hydroxybutyric acid (other names include:
318 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic
319 acid; sodium oxybate; sodium oxybutyrate);

320 (2) Mecloqualone;

321 (3) Methaqualone.

322 (e) **Stimulants.** Any material, compound, mixture or
323 preparation which contains any quantity of the following central
324 nervous system stimulants including optical salts, isomers and
325 salts of isomers unless specifically excepted or unless listed in
326 another schedule:

327 (1) Aminorex;

328 (2) N-benzylpiperazine (also known as BZP;
329 1-benzylpiperazine);

330 (* * *3) Cathinone * * *;

331 (* * *4) Fenethylamine;

332 (5) Methcathinone;

333 (* * *6) 4-methylaminorex (also known as
334 2-amino-4-methyl-5-phenyl-2-oxazoline);

335 (* * *7) N-ethylamphetamine;

336 (* * *8) Any material, compound, mixture or
337 preparation which contains any quantity of
338 N,N-dimethylamphetamine. (Other names include:
339 N,N,-alpha-trimethyl-benzeneethanamine, and
340 N,N-alpha-trimethylphenethylamine);



366 (2) Dextropropoxyphene, including its salts
367 (Darvon, Darvon-N; also found in Darvon compound and Darvocet-N,
368 etc.).

369 (b) **Depressants.** Any material, compound, mixture or
370 preparation which contains any quantity of the following
371 substances:

- 372 (1) Alprazolam;
- 373 (2) Barbital;
- 374 (3) Bromazepam;
- 375 (4) Camazepam;
- 376 (5) Carisoprodol;
- 377 (6) Chloral betaine;
- 378 (7) Chloral hydrate;
- 379 (8) Chlordiazepoxide and its salts, but does not
380 include chlordiazepoxide hydrochloride and clidinium bromide or
381 chlordiazepoxide and esterified estrogens;
- 382 (9) Clobazam;
- 383 (10) Clonazepam;
- 384 (11) Clorazepate;
- 385 (12) Clotiazepam;
- 386 (13) Cloxazolam;
- 387 (14) Delorazepam;
- 388 (15) Diazepam;
- 389 (16) Dichloralphenazone;
- 390 (17) Estazolam;



- 391 (18) Ethchlorvynol;
- 392 (19) Ethinamate;
- 393 (20) Ethyl loflazepate;
- 394 (21) Fludiazepam;
- 395 (22) Flunitrazepam;
- 396 (23) Flurazepam;
- 397 (24) Fospropofol;
- 398 (25) Halazepam;
- 399 (26) Haloxazolam;
- 400 (27) Ketazolam;
- 401 (28) Loprazolam;
- 402 (29) Lorazepam;
- 403 (30) Lormetazepam;
- 404 (31) Mazindol;
- 405 (32) Mebutamate;
- 406 (33) Medazepam;
- 407 (34) Meprobamate;
- 408 (35) Methohexital;
- 409 (36) Methylphenobarbital;
- 410 (37) Midazolam;
- 411 (38) Nimetazepam;
- 412 (39) Nitrazepam;
- 413 (40) Nordiazepam;
- 414 (41) Oxazepam;
- 415 (42) Oxazolam;



- 416 (43) Paraldehyde;
- 417 (44) Petrichloral;
- 418 (45) Phenobarbital;
- 419 (46) Pinazepam;
- 420 (47) Prazepam;
- 421 (48) Quazepam;
- 422 (49) Temazepam;
- 423 (50) Tetrazepam;
- 424 (51) Triazolam;
- 425 (52) Zaleplon;
- 426 (53) Zolpidem;
- 427 (54) Zopiclone.

428 (c) Fenfluramine.

429 (d) Lorcaserin. Any material, compound, mixture, or
430 preparation which contains any quantity of Lorcaserin, including
431 its salts, isomers, and salts of such isomers, whenever the
432 existence of such salts, isomers, and salts of isomers is
433 possible.

434 (* * *e) **Stimulants.** Any material, compound, mixture
435 or preparation which contains any quantity of the following
436 substances:

- 437 (1) Diethylpropion;
- 438 (2) Phentermine;
- 439 (3) Pemoline (including any organometallic
440 complexes and chelates thereof);



- 441 (4) Pipradrol;
- 442 (5) Sibutramine;
- 443 (6) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
- 444 (7) Cathine ((+/-) Norpseudoephedrine);
- 445 (8) Fencamfamin;
- 446 (9) Fenproporex;
- 447 (10) Mefenorex;
- 448 (11) Modafinil.

449 (* * *f) **Other substances.**

- 450 (1) Butorphanol (including its optical isomers);
- 451 (2) Tramadol.

452 (B) Any material, compound, mixture or preparation which
453 contains any quantity of a Schedule IV controlled substance and is
454 listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24,
455 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions
456 of the Uniform Controlled Substances Law.

457 **SECTION 3.** Section 41-29-176, Mississippi Code of 1972, is
458 amended as follows:

459 41-29-176. (1) When any property other than a controlled
460 substance, raw material or paraphernalia, the value of which does
461 not exceed Twenty Thousand Dollars (\$20,000.00), is seized under
462 the Uniform Controlled Substances Law, the property may be
463 forfeited by the administrative forfeiture procedures provided for
464 in this section.



465 (2) The attorney for or any representative of the seizing
466 law enforcement agency shall provide notice of intention to
467 forfeit the seized property administratively, either by certified
468 mail, return receipt requested, or by personal delivery, to all
469 persons who are required to be notified pursuant to Section
470 41-29-177(2) * * *.

471 (3) * * * If notice of intention to forfeit the seized
472 property administratively cannot be given as provided in
473 subsection (2) of this section because of refusal, failure to
474 claim, insufficient address or any other reason, the attorney for
475 or representative of the seizing law enforcement agency shall
476 provide notice by publication in a newspaper of general
477 circulation in the county in which the seizure occurred for once a
478 week for three (3) consecutive weeks. * * *

479 (4) Notice pursuant to subsections (2) and (3) of this
480 section shall include the following information:

- 481 (a) A description of the property;
- 482 (b) The approximate value of the property;
- 483 (c) The date and place of the seizure;
- 484 (d) The connection between the property and the
485 violation of the Uniform Controlled Substances Law;
- 486 (e) The instructions for filing a request for judicial
487 review; and



488 (f) A statement that the property will be forfeited to
489 the seizing law enforcement agency if a request for judicial
490 review is not timely filed.

491 (5) Any person claiming an interest in property which is the
492 subject of a notice under this section may, within thirty (30)
493 days after receipt of the notice or of the date of the first
494 publication of the notice, file a petition to contest forfeiture
495 signed by the claimant in the county court, if a county court
496 exists, or otherwise in the circuit court of the county in which
497 the seizure is made or the county in which the criminal
498 prosecution is brought, in order to claim an interest in the
499 property. Upon the filing of the petition and the payment of the
500 filing fees, service of the petition shall be made on the attorney
501 for or representative of the seizing law enforcement agency, and
502 the proceedings shall thereafter be governed by the rules of civil
503 procedure.

504 (6) If no petition to contest forfeiture is timely filed,
505 the attorney for the seizing law enforcement agency shall prepare
506 a written declaration of forfeiture of the subject property and
507 the forfeited property shall be used, distributed or disposed of
508 in accordance with the provisions of Section 41-29-181 * * *.

509 **SECTION 4.** Sections 2 and 3 of this act shall take effect
510 and be in force from and after July 1, 2014, and Section 1 of this
511 act shall take effect and be in force from and after its passage.



**Further, amend by striking the title in its entirety and
inserting in lieu thereof the following:**

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,
2 TO ADD CERTAIN HALLUCINOGENIC SUBSTANCES TO SCHEDULE I OF THE
3 UNIFORM CONTROLLED SUBSTANCES ACT AND TO EXEMPT CERTAIN USES OF
4 CANNABIDIOL; TO AMEND SECTION 41-29-119, MISSISSIPPI CODE OF 1972,
5 TO ADD LORCASERIN TO SCHEDULE IV OF THE UNIFORM CONTROLLED
6 SUBSTANCES ACT; TO AMEND SECTION 41-29-176, MISSISSIPPI CODE OF
7 1972, TO REVISE THE ADMINISTRATIVE FORFEITURE OF PROPERTY UNDER
8 THE UNIFORM CONTROLLED SUBSTANCES LAW; AND FOR RELATED PURPOSES.

